Summary: AstraZeneca PLC

  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: AstraZeneca PLC

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: AstraZeneca PLC

  • With an enterprise value anticipated at 3.54 times the sales for the current fiscal year, the company turns out to be overvalued.
  • The company appears highly valued given the size of its balance sheet.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The company's earnings releases usually do not meet expectations.

Ratings Chart: AstraZeneca PLC

surperformance-ratings-chart ASTRAZENECA-PLC
Source: Surperformance

ESG chart: AstraZeneca PLC

esg-ratings-chart ASTRAZENECA-PLC
Source: Refinitiv

Add to a list
Composite Fundamentals Composite Valuation Composite Momentum Capi. ($)
211B
744B
493B
359B
311B
261B
235B
205B
147B
146B
Average 311.16B
Weighted average by Cap.
See all sector ratings
Investor Rating
Trading Rating
ESG Refinitiv
B+

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. Ratings AstraZeneca PLC